AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The capabilities he built position us to advance what we call convergent innovation and strengthen our ability to serve patients in the years ahead

  60% confidence

• Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift

  60% confidence

• Reese encouraged the early adoption of technology and artificial intelligence across all facets of the business, in particular R&D

  60% confidence

• Reese led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities during his tenure

  60% confidence

Cited in these Via News reports

• 88% of Global Executives Regret Weak AI Foundations as Agentic Infrastructure Goes Live →
• Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
• Dell and NVIDIA Launch GPU Platform as Global Enterprises Race to Lock In Institutional AI Advantage →
• Dell and NVIDIA Launch Global AI Data Platform as Infrastructure War Reshapes Enterprise Stack Worldwide →
• Dell and NVIDIA's Global Infrastructure Push Signals Who Will Control Enterprise AI →
• Dell, SAP, Oracle Compete Globally for the Layer That Controls Enterprise AI →
• Enterprise AI Winners Already Have the Data: Incumbents Are Pulling Ahead Globally →
• FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies →
• From Co-Pilots to Autonomous Agents: Snowflake, NVIDIA, and Dell Build the Global AI Infrastructure Layer →
• GPU Lead Times Reach 52 Weeks as Global Enterprise AI Race Moves Beyond Copilots to Autonomous Agents →
• Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents →
• Global Enterprises Integrate AI Agents as Autonomous Workforce Members →
• Global Enterprises Replace AI Assistants With Autonomous Agents, Forcing Deep Operational Restructuring →
• Infrastructure, Not Models, Now Decides the Global Enterprise AI Race →
• Proprietary Data Beats Model Access in Global Enterprise AI Race →
• Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →
• Snowflake, EXL, and Netskope Ship Agent Infrastructure as Global Enterprise Tech Stacks Face Replacement →
• Vepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug Valuations →